Home/Filings/4/0001003642-18-000079
4//SEC Filing

Boothe Douglas 4

Accession 0001003642-18-000079

CIK 0001003642other

Filed

May 7, 8:00 PM ET

Accepted

May 8, 4:13 PM ET

Size

12.0 KB

Accession

0001003642-18-000079

Insider Transaction Report

Form 4
Period: 2018-05-04
Boothe Douglas
President, Generics Division
Transactions
  • Disposition to Issuer

    Restricted Common Stock

    2018-05-0441,7560 total
  • Disposition to Issuer

    Stock Option (Right to Buy)

    2018-05-0456,2320 total
    Exercise: $9.35Exp: 2027-03-02Common Stock (56,232 underlying)
  • Disposition to Issuer

    Common Stock

    2018-05-0414,1450 total
  • Disposition to Issuer

    Stock Option (Right to Buy)

    2018-05-0450,5000 total
    Exercise: $24.42Exp: 2026-08-01Common Stock (50,500 underlying)
Footnotes (3)
  • [F1]Common Stock disposed of pursuant to the terms of the Business Combination Agreement, dated as of October 17, 2017 (the "BCA"), by and among Impax Laboratories, Inc., Atlas Holdings, Inc. ("Holdco"), K2 Merger Sub Corporation and Amneal Pharmaceuticals LLC, as amended by Amendment No. 1, dated as of November 21, 2017, and Amendment No. 2, dated as of December 16, 2017, according to which each share of Common Stock held by the reporting person was converted into the right to receive one share of Class A common stock of Holdco ("Class A Common Stock").
  • [F2]Shares of restricted common stock disposed of pursuant to the terms of the BCA, according to which each share of restricted stock held by the reporting person fully vested and was exchanged for one share of Class A Common Stock. Amount represents net amount of shares exchanged after required tax withholding with respect to such vesting.
  • [F3]Options disposed of pursuant to the terms of the BCA, according to which each Option held by the reporting person fully vested and was exchanged for an option to acquire a number of shares of Class A Common Stock equal to the number of shares of Common Stock subject to such Option in connection with the closing of the transactions contemplated by the BCA, at a per-share exercise price equal to the per-share exercise price of such Option.

Issuer

Impax Laboratories, LLC

CIK 0001003642

Entity typeother

Related Parties

1
  • filerCIK 0001566118

Filing Metadata

Form type
4
Filed
May 7, 8:00 PM ET
Accepted
May 8, 4:13 PM ET
Size
12.0 KB